《大行報告》花旗一舉升綠城中國(03900.HK)評級至「買入」 目標價上調至14.8元
花旗發表報告,指綠城中國(03900.HK)積極購買土地和具競爭力資金成本有利推動其增長,銷售表現領先同行,相信能抵銷第二大股東減持和與母企關係的不利因素。該行將綠城中國評級由「沽售」一舉上調至「買入」,目標價由8.48元大幅上調至14.8元。
花旗料綠城中國2021年銷售額按年上升21%至2,600億元人民幣(下同),2022年增長15%,在2021至2023年間入賬毛利率可能會持續下滑至介乎19%至21%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.